The German company publishes partial data of its phase III for its treatment for Fibrinogen deficiency
Grifols has achieved the first success with Biotest, its brand new acquisition for 1,453 million euros. The German company has recently announced promising intermediate results of its treatment for Fibrinogen deficiency (a protein
